SG11201601306QA - An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease - Google Patents
An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's diseaseInfo
- Publication number
- SG11201601306QA SG11201601306QA SG11201601306QA SG11201601306QA SG11201601306QA SG 11201601306Q A SG11201601306Q A SG 11201601306QA SG 11201601306Q A SG11201601306Q A SG 11201601306QA SG 11201601306Q A SG11201601306Q A SG 11201601306QA SG 11201601306Q A SG11201601306Q A SG 11201601306QA
- Authority
- SG
- Singapore
- Prior art keywords
- alzheimer
- disease
- treatment
- receptor antagonist
- cholinesterase inhibitor
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 title 1
- 239000000544 cholinesterase inhibitor Substances 0.000 title 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306228 | 2013-09-09 | ||
PCT/EP2014/069168 WO2015032966A1 (en) | 2013-09-09 | 2014-09-09 | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201601306QA true SG11201601306QA (en) | 2016-03-30 |
Family
ID=49230670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201601306QA SG11201601306QA (en) | 2013-09-09 | 2014-09-09 | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160256449A1 (en) |
EP (1) | EP3043799A1 (en) |
JP (1) | JP2016529307A (en) |
KR (1) | KR20160048930A (en) |
CN (1) | CN105764510A (en) |
SG (1) | SG11201601306QA (en) |
WO (1) | WO2015032966A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2647377A1 (en) * | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
SI3500253T1 (en) | 2016-08-18 | 2020-10-30 | Suven Life Sciences Limited | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
NZ761037A (en) * | 2017-07-03 | 2022-10-28 | Suven Life Sciences Ltd | New uses of a pure 5-ht6 receptor antagonist |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
EP3973586A4 (en) * | 2019-05-21 | 2023-01-11 | La Pharma Tech Inc. | Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2870846B1 (en) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | TETRAHYDROISOQUINOLYLSULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
JP2009541423A (en) * | 2006-06-23 | 2009-11-26 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | Combination of a cholinesterase inhibitor and a compound having affinity for 5-HT6 receptor |
CA2766154C (en) * | 2009-06-26 | 2015-04-07 | Beverly C. Langevin | Novel fumarate salts of a histamine h3 receptor antagonist |
FR2953521B1 (en) * | 2009-12-09 | 2011-11-18 | Servier Lab | NOVEL AZABICYCLO [3.1.0] HEX-2-YL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
AR080374A1 (en) * | 2010-03-05 | 2012-04-04 | Sanofi Aventis | PROCEDURE FOR THE PREPARATION OF 2- (CYCLOHEXILMETIL) -N- (2 - ((2S) -1-METHYLPIRROLIDIN-2-IL) ETIL) - 1,2,3,4-TETRAHYDROISOQUINOLIN-7- SULFONAMIDE |
FR2976286B1 (en) * | 2011-06-08 | 2013-05-24 | Servier Lab | 4- {3- [TRANS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} BENZAMIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
EP2647377A1 (en) * | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
EP2745876A1 (en) * | 2012-12-21 | 2014-06-25 | Prous Institute for Biomedical Research, S.A. | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
-
2014
- 2014-09-09 EP EP14761845.8A patent/EP3043799A1/en not_active Withdrawn
- 2014-09-09 CN CN201480061169.6A patent/CN105764510A/en active Pending
- 2014-09-09 JP JP2016539580A patent/JP2016529307A/en active Pending
- 2014-09-09 WO PCT/EP2014/069168 patent/WO2015032966A1/en active Application Filing
- 2014-09-09 KR KR1020167008247A patent/KR20160048930A/en not_active Withdrawn
- 2014-09-09 SG SG11201601306QA patent/SG11201601306QA/en unknown
-
2016
- 2016-03-08 US US15/063,977 patent/US20160256449A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3043799A1 (en) | 2016-07-20 |
WO2015032966A1 (en) | 2015-03-12 |
JP2016529307A (en) | 2016-09-23 |
KR20160048930A (en) | 2016-05-04 |
CN105764510A (en) | 2016-07-13 |
US20160256449A1 (en) | 2016-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202012656WA (en) | Heterocyclic compounds useful in the treatment of disease | |
IL285843A (en) | Ibrutinib for use in the treatment of graft-versus-host disease | |
IL243976A0 (en) | Kdm1a inhibitors for the treatment of disease | |
PL2968218T3 (en) | Combination for the treatment of parkinson's disease | |
EP3019491A4 (en) | Kinase inhibitors for the treatment of disease | |
GB201321743D0 (en) | Therapeutic agents | |
GB201321746D0 (en) | Therapeutic agents | |
GB201321738D0 (en) | Therapeutic Agents | |
PL3811943T3 (en) | Compound for use in the treatment of ocular disorders | |
GB201321736D0 (en) | Therapeutic agents | |
GB201321729D0 (en) | Therapeutic agents | |
EP2882439A4 (en) | AGENTS INDUCING APOPTOSIS | |
SG10201912275YA (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders | |
GB201321728D0 (en) | Therapeutic agents | |
GB201321733D0 (en) | Therapeutic agents | |
GB201321730D0 (en) | Therapeutic agents | |
GB201321739D0 (en) | Therapeutic agents | |
GB201321741D0 (en) | Therapeutic agents | |
GB201321740D0 (en) | Therapeutic agents | |
GB201321732D0 (en) | Therapeutic agents | |
GB201321734D0 (en) | Therapeutic Agents | |
SG11201601306QA (en) | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease | |
GB201321744D0 (en) | Therapeutic agents | |
GB201321737D0 (en) | Therapeutic Agents | |
GB201321742D0 (en) | Therapeutic agents |